King/Mylan Merger Will Provide Critical Mass To Develop Palatin's ED Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
King will pay up to $250 mil. to in-license the Phase II agent PT-141 for female sexual dysfunction and erectile dysfunction. King says the melanocortin receptor agonist will provide better safety and efficacy compared to the currently marketed PDE-5 inhibitors.
You may also be interested in...
King/Palatin Put Phase III Plans For Erectile Dysfunction Product On Hold
Risk/benefit profile for bremelanotide unacceptable for first-line use, but compound may have value as second-line therapy for PDE-5 nonresponders, FDA says.
King/Palatin Put Phase III Plans For Erectile Dysfunction Product On Hold
Risk/benefit profile for bremelanotide unacceptable for first-line use, but compound may have value as second-line therapy for PDE-5 nonresponders, FDA says.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.